Pulmonary Pharmacology & Therapeutics

Papers
(The TQCC of Pulmonary Pharmacology & Therapeutics is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
The promoting role of Cx43 on the proliferation and migration of arterial smooth muscle cells for angiotensin II-dependent hypertension73
Editorial Board53
Preliminary study regarding the predicted body weight-based dexamethasone therapy in patients with COVID-19 pneumonia43
Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis39
Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis37
Efficacy and safety of non-prostanoid prostacyclin receptor agonist for pulmonary hypertension: A meta-analysis37
Editorial Board35
Editorial Board30
Editorial Board25
Effect of centrally and peripherally acting GABAB agonism on the healthy human cough reflex25
Risk factors associated with increased discontinuation rate of trimethoprim–sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study22
Improvement of asthma control in adult patients using extrafine inhaled beclomethasone/formoterol fixed combination as maintenance therapy as well as maintenance and reliever therapy – CONTROL study21
The incidence and prognosis of other iatrogenic immunodeficiency-associated lymphoproliferative disorders of the lung related to methotrexate: A retrospective study20
CG223, a novel BET inhibitor, exerts TGF-β1-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis19
Mechanistic insights into the amelioration effects of lipopolysaccharide-induced acute lung injury by baicalein: An integrated systems pharmacology study and experimental validation19
Editorial Board18
Knockdown of HDAC10 inhibits POLE2-mediated DNA damage repair in NSCLC cells by increasing SP1 acetylation levels18
Nebulized amphotericin B for preventing exacerbations in allergic bronchopulmonary aspergillosis: A systematic review and meta-analysis18
Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers17
Enlightening clinical and therapeutic heterogeneity in thoracic actinomycosis: A review in bronchiectasis and non-bronchiectasis patients17
Interaction between fluticasone furoate and umeclidinium in passively sensitized isolated human airways16
Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)16
Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry16
Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers15
Ensifentrine approval: A milestone in the treatment of COPD13
FTO promotes gefitinib-resistance by enhancing PELI3 expression and autophagy in non-small cell lung cancer13
Corrigendum to “Presence and function of β-adrenergic receptors in primary equine bronchial epithelia cells” [Pulm Pharmacol Ther. (2020 Apr) 61 101897] DOI: 10.1016/j.pupt.2020.10189712
HDAC8-inhibitor PCI-34051-induced exosomes inhibit human bronchial smooth muscle cell proliferation via miR-381-3p mediated TGFB311
Shedding light on vitamin D in tuberculosis: A comprehensive review of clinical trials and discrepancies11
Up-regulation of PPAR-γ involved in the therapeutic effect of icariin on cigarette smoke-induced inflammation11
Development of an inhaled anti-TSLP therapy for asthma10
Chrysin prevents lipopolysaccharide-induced acute lung injury in mice by suppressing the IRE1α/TXNIP/NLRP3 pathway10
Applicability of mouse models for induction of severe acute lung injury10
Differential distribution of ivacaftor and its metabolites in plasma and human airway epithelia9
Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K/AKT signaling pathway9
IL-10RA promotes lung cancer cell proliferation by increasing fatty acid oxidation via STAT3 signaling pathway9
The roles of immune system and autoimmunity in pulmonary arterial hypertension: A review9
Impact of beta blockers on resting respiratory rate in older adults: A cross-sectional study9
Efficacy and safety of selexipag, an oral prostacyclin receptor agonist for the treatment of pulmonary hypertension: A meta-analysis9
Dihydroquercetin (DHQ) ameliorates LPS-induced acute lung injury by regulating macrophage M2 polarization through IRF4/miR-132-3p/FBXW7 axis8
Scoping review: The state of research on cryptogenic organizing pneumonia therapeutics8
An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome8
Serum dipeptidyl peptidase-4 and eosinophil cationic protein levels in patients of bronchial asthma8
Editorial Board7
Editorial Board7
Editorial Board7
Corrigendum to “Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/indacaterol/glycopyrronium in patients 7
Evaluation of the prophylactic effect of hydroxychloroquine on people in close-contact with patients with COVID-197
Dose bridging data for mometasone furoate in once-daily fixed-dose inhaled combinations of mometasone furoate/indacaterol and mometasone furoate/ indacaterol/glycopyrronium in patients with asthma7
Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study7
Evaluation of body weight–based dosing, alternative dosing regimens, and treatment interruptions for α1-proteinase inhibitors and implications on biochemical efficacy in patients with α1-antitrypsin d6
Editorial Board6
The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers6
Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients6
Editorial Board6
0.043091058731079